Sandhya Girish

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2010 · 764 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 596 citations

Medicine, Oncology, Pharmacology +17

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Ian E. Krop, Patricia LoRusso, Kathy D. Miller et al. · Journal of Clinical Oncology · 2012 · 362 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Sandhya Girish, Manish Gupta, Bei Wang et al. · Cancer Chemotherapy and Pharmacology · 2012 · 265 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)

Hirdesh Uppal, Estelle Doudement, Kaushiki Mahapatra et al. · Clinical Cancer Research · 2014 · 211 citations

Medicine, Hematology, Pharmacology +17